NCT01820065

Brief Summary

Although contemporary cataract surgery has made tremendous strides in technological advancement, posterior capsular opacification (PCO) is still the most frequent long-term complication leading to decreased visual functions and thereby dissatisfying results. A great deal of effort has been made to develop new ways to prevent the formation of PCO. A key factor, widely discussed in literature, is the material and design of the intraocular lense (IOL) edge that can lead to PCO prevention. It is still not clear whether the sharp-edged IOL produces less PCO because of its optic geometry alone or whether the biomaterial contributes to the inhibition of PCO. With the clinical introduction of the single-piece acrylic hydrophobic IOLs with some optic and haptic design differences compared with three-piece acrylic hydrophobic IOLs, it has become possible to determine the influence of IOL material and design on PCO prevention. It is well established that the development of PCO is a dynamic process and that a longer follow-up time is correlated with a higher degree of PCO. So far, there have been prospective clinical studies on the clinical results of single and three-piece acrylic hydrophobic foldable IOLs. However, the question as to as to whether the PCO further increases or becomes stable or regresses on a long-term basis has not yet been answered. Since there is paucity of available literature that prospectively evaluates the development of PCO with the implantation of the single-piece SN60AT hydrophobic acrylic IOL on a long-term basis, the investigators decided to observe the degree of development of PCO at 5 years after cataract surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
390

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2005

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
6.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

March 25, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 28, 2013

Completed
Last Updated

March 28, 2013

Status Verified

March 1, 2013

Enrollment Period

6.3 years

First QC Date

March 25, 2013

Last Update Submit

March 27, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Posterior Capsule Opacification

    Evaluation of PCO (EPCO) scores in the area of the intraocular lens (IOL) optic and in the central 3mm zone at 5 years after surgery

    5 years followup

Secondary Outcomes (1)

  • EPCO Score and EPCO area with total on and part on anterior capsulorhexis cover over optic

    5 years postoperatively

Other Outcomes (1)

  • Change in PCO at different followup intervals

    upto 5 years postoperatively

Study Arms (1)

Patients undergoing phacoemulsification

Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)

Procedure: Cataract surgery with IOL implantation

Interventions

Phacoemulsification with implantation of single piece Acrysof IOL

Patients undergoing phacoemulsification

Eligibility Criteria

Age40 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing phacoemulsification for age-related uncomplicated phacoemulsification

You may qualify if:

  • patients with uncomplicated age-related cataract who were otherwise healthy

You may not qualify if:

  • a history of diabetes mellitus (DM),
  • patients with glaucoma,
  • high myopia (axial length \> 27.0 mm),
  • pseudoexfoliation,
  • traumatic cataract,
  • subluxated cataract,
  • previous ocular surgeries, and
  • allergy to dilating drops.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Iladevi Cataract & IOL Research Centre

Ahmedabad, Gujarat, 380052, India

Location

MeSH Terms

Interventions

Cataract Extraction

Intervention Hierarchy (Ancestors)

Refractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Abhay R Vasavada, MS, FRCS

    Iladevi Cataract & IOL Research Centre

    PRINCIPAL INVESTIGATOR
  • Abhay R Vasavada, MS,FRCS

    Iladevi Cataract & IOL Research Centre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, Iladevi Cataract and IOL Research Center

Study Record Dates

First Submitted

March 25, 2013

First Posted

March 28, 2013

Study Start

June 1, 2005

Primary Completion

October 1, 2011

Study Completion

October 1, 2011

Last Updated

March 28, 2013

Record last verified: 2013-03

Locations